Opko Health Inc. (NASDAQ:OPK) has been given an average rating of “Buy” by the six brokerages that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $9.50.
Several research analysts recently weighed in on the stock. BidaskClub upgraded shares of Opko Health from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 24th. ValuEngine upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research report on Friday, September 7th. Barrington Research restated a “buy” rating and set a $7.00 price target on shares of Opko Health in a research report on Monday, November 12th. Finally, Zacks Investment Research upgraded shares of Opko Health from a “hold” rating to a “buy” rating and set a $4.00 price target for the company in a research report on Friday, November 30th.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in shares of Opko Health by 2.1% during the 3rd quarter. Vanguard Group Inc. now owns 29,660,750 shares of the biotechnology company’s stock worth $102,626,000 after purchasing an additional 614,442 shares during the last quarter. Teachers Advisors LLC raised its position in shares of Opko Health by 3.5% during the 3rd quarter. Teachers Advisors LLC now owns 754,427 shares of the biotechnology company’s stock worth $2,610,000 after purchasing an additional 25,222 shares during the last quarter. MetLife Investment Advisors LLC raised its position in shares of Opko Health by 38.2% during the 3rd quarter. MetLife Investment Advisors LLC now owns 207,467 shares of the biotechnology company’s stock worth $718,000 after purchasing an additional 57,299 shares during the last quarter. Pacer Advisors Inc. acquired a new position in shares of Opko Health during the 3rd quarter worth about $198,000. Finally, BlueMountain Capital Management LLC acquired a new position in shares of Opko Health during the 3rd quarter worth about $187,000. Hedge funds and other institutional investors own 26.20% of the company’s stock.
Shares of Opko Health stock traded up $0.03 during trading hours on Monday, reaching $3.28. The stock had a trading volume of 4,572,311 shares, compared to its average volume of 4,052,550. The company has a market cap of $1.82 billion, a P/E ratio of -11.31 and a beta of 1.90. Opko Health has a twelve month low of $2.66 and a twelve month high of $6.40. The company has a debt-to-equity ratio of 0.03, a quick ratio of 0.78 and a current ratio of 0.91.
Opko Health (NASDAQ:OPK) last issued its quarterly earnings data on Friday, November 9th. The biotechnology company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03. The business had revenue of $250.00 million during the quarter, compared to the consensus estimate of $264.04 million. Opko Health had a negative net margin of 30.24% and a negative return on equity of 8.68%. The company’s revenue was up 1.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.08) earnings per share. Equities research analysts forecast that Opko Health will post -0.21 EPS for the current year.
Opko Health Company Profile
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.
Featured Story: Analyzing a company’s cash flow statement
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.